سعر اريكسترا 5مجم /0.4مل حقن 10 سرنجات معبأة للحقن تحت الجلد 2026

Arixtra 5 mg/0.4 ml solution for subcutaneous injection (fondaparinux sodium) in pre-filled syringes, a synthetic selective factor Xa inhibitor anticoagulant; pack of 10 syringes; listed under GlaxoSmithKline > Phoenix-Egypt in Egypt.

• Treatment of acute deep vein thrombosis in adultsPopulation: AdultsEuropean Medicines Agency (EMA)
• Treatment of acute pulmonary embolism in adults (except haemodynamically unstable patients or those requiring thrombolysis or embolectomy)Population: AdultsEuropean Medicines Agency (EMA)
• Treatment of venous thromboembolism in paediatric patients aged 1 year or older weighing at least 10 kg (US label only)Population: Paediatric patients (1 year or older, at least 10 kg)DailyMed (U.S. National Library of Medicine)

• Bleeding complications are the most common serious reactions (including rare intracranial/intracerebral and retroperitoneal bleeding). Common: anaemia, post-operative haemorrhage, haematoma, haematuria, haemoptysis, gingival bleeding, purpura, epistaxis, GI bleeding. Uncommon: thrombocytopenia, headache, nausea, vomiting, abnormal liver function tests, rash, pruritus, oedema, fever. Rare: allergic reactions, hypokalaemia, injection-site reaction.International label, same product · European Medicines Agency (EMA)
• Local injection-site irritation (bleeding, rash, pruritus); asymptomatic reversible aminotransferase elevations; postmarketing: epidural/spinal hematoma, thrombocytopenia with thrombosis resembling HIT, aPTT elevation with bleeding, angioedema/anaphylaxis.International label, same product · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to fondaparinux or excipients; active clinically significant bleeding; acute bacterial endocarditis; severe renal impairment (creatinine clearance <30 ml/min).International label, same product · European Medicines Agency (EMA)
• Also thrombocytopenia with a positive in vitro anti-platelet antibody test in the presence of fondaparinux; and history of serious hypersensitivity (angioedema, anaphylactoid/anaphylactic reactions).International label, same product · DailyMed (U.S. National Library of Medicine)

• Boxed warning: epidural or spinal hematomas, possibly causing long-term or permanent paralysis, may occur with neuraxial anaesthesia or spinal puncture; risk increased by indwelling epidural catheters, drugs affecting haemostasis, traumatic/repeated punctures or spinal deformity/surgery.International label, same product · DailyMed (U.S. National Library of Medicine)
• In patients treated for VTE (not prophylaxis), spinal/epidural anaesthesia should not be used for surgical procedures.International label, same product · European Medicines Agency (EMA)
• Use with caution in patients at increased risk of haemorrhage (bleeding disorders, platelets <50,000/mm3, active ulcerative GI disease, recent intracranial haemorrhage, recent brain/spinal/ophthalmic surgery, surgery within 3 days); avoid concomitant desirudin, fibrinolytics, GP IIb/IIIa antagonists, heparin, heparinoids or LMWH.International label, same product · European Medicines Agency (EMA)

• Agents increasing bleeding risk (desirudin, fibrinolytics, GP IIb/IIIa antagonists, heparin, heparinoids, LMWH)Should not be given concomitantly because of increased haemorrhage risk.European Medicines Agency (EMA)
• Antiplatelet agents (acetylsalicylic acid, dipyridamole, clopidogrel, ticlopidine, sulfinpyrazone) and NSAIDsUse with caution; close monitoring if co-administration is essential (no pharmacokinetic interaction with aspirin or piroxicam).European Medicines Agency (EMA)
• Warfarin (vitamin K antagonists)No pharmacokinetic interaction; fondaparinux 10 mg did not affect INR monitoring of warfarin; given together as part of VTE treatment.European Medicines Agency (EMA)

• No clinical data on exposed pregnancies; animal studies are insufficient. Should not be prescribed to pregnant women unless clearly necessary.International label, same product · European Medicines Agency (EMA)
• Published literature and postmarketing reports have not shown a clear association with adverse developmental outcomes; low placental transfer was seen in four treated women; untreated VTE and anticoagulant-related haemorrhage carry maternal and fetal risks.International label, same product · DailyMed (U.S. National Library of Medicine)
• Excreted in rat milk; not known whether excreted in human milk. Breast-feeding is not recommended during treatment (oral absorption by the child is unlikely).International label, same product · European Medicines Agency (EMA)

• Fondaparinux sodium: Binds selectively to antithrombin III and potentiates (about 300-fold) its neutralisation of factor Xa, interrupting the coagulation cascade and inhibiting thrombin formation; does not inactivate thrombin and has no known effect on platelet function.